|Baxter CEO Robert Parkinson|
The deal: Baxter buys Gambro
The price tag: $3.9 billion
Why it matters: Baxter ($BAX) and Gambro first announced this massive deal in December 2012, and it took 9 months to finish. Now that it is complete, Baxter gains a much larger, even dominant share of the global renal device market. It wasn't easy to get there. EU regulators made Baxter sell off its continuous renal replacement therapy in order to address monopoly concerns. With that done, Baxter's global dialysis presence gets even bigger as it absorbs Gambro's dominant presence in Latin America and Asia. With Gambro as an infusion, Baxter said it would boost growth.
"Together, we will advance the state of dialysis care for patients with kidney disease worldwide," Baxter CEO Robert Parkinson said in a statement at the time the deal closed last September.
Baxter wins EU sign-off for $4B Gambro deal
Baxter finally closes $4B Gambro deal, eyes dialysis dominance